Mercilon

Desogestrel/Ethinylestradiol, the active ingredient in Mercilon, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Mercilon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mercilon, a combined oral contraceptive, is indicated for hormonal regulation to prevent pregnancy and manage menstrual‑related conditions.

Contraception: prevents unintended pregnancy in women of childbearing potential. Menstrual cycle regulation: provides predictable monthly bleeding and reduces cycle irregularities. Moderate acne treatment: improves skin lesions associated with hormonal acne in women.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Spotting or breakthrough bleeding: irregular light bleeding. - Mood changes: irritability or mild depression. - Weight fluctuation: slight increase or fluid retention.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in legs. - Pulmonary embolism: clot traveling to lungs. - Stroke or transient ischemic attack: neurological events. - Myocardial infarction: heart attack risk. - Severe allergic reaction: rash, swelling, anaphylaxis. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before initiating Mercilon, consider the following safety measures. - Cardiovascular risk assessment: evaluate history of thrombosis, smoking, hypertension. - Pregnancy status: discontinue if pregnancy is confirmed. - Age and smoking: avoid use in women over 35 who smoke. - Hepatic function: use with caution in liver disease. - Drug interaction review: assess concomitant medications that affect estrogen metabolism. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Mercilon may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): may markedly reduce contraceptive efficacy. - Protease inhibitors (e.g., ritonavir): can increase estrogen exposure and risk of side effects.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may raise plasma hormone levels. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): can increase bleeding tendency. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and raise INR.